Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on YouTube
  • Follow jrheum on Instagram
  • Follow jrheum on RSS
Research ArticleArticle

High-density Lipoprotein Profiling Changes in Patients with Rheumatoid Arthritis Treated with Tumor Necrosis Factor Inhibitors: A Cohort Study

Anna Jamnitski, Johannes H. Levels, Inge A. van den Oever and Michael T. Nurmohamed
The Journal of Rheumatology June 2013, 40 (6) 825-830; DOI: https://doi.org/10.3899/jrheum.121358
Anna Jamnitski
From the Jan van Breemen Research Institute; Academic Medical Centre Amsterdam; and VU University Medical Centre, Amsterdam, The Netherlands.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Johannes H. Levels
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Inge A. van den Oever
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael T. Nurmohamed
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: m.nurmohamed@reade.nl
  • Article
  • Figures & Data
  • References
  • Info & Metrics
  • PDF
  • eLetters
PreviousNext
Loading

Abstract

Objective. We investigated changes in high-density lipoprotein (HDL) profiling in patients with rheumatoid arthritis who started treatment by taking tumor necrosis factor (TNF) inhibitors. The patients were stratified for European League Against Rheumatism (EULAR) response.

Methods. A group of 100 patients naive for TNF inhibitors at baseline were randomly selected from 204 adalimumab-treated and 203 etanercept-treated patients on the basis of their EULAR response. HDL profiling was measured using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry.

Results. In EULAR good responders, mass charged markers representing serum amyloid A (SAA-1 and -2) decreased significantly after 4 months’ therapy. There were no significant differences in HDL profiling in EULAR nonresponders.

Conclusion. Effective suppression of inflammation with TNF inhibitors results in favorable changes in HDL composition.

Key Indexing Terms:
  • RHEUMATOID ARTHRITIS
  • HIGH-DENSITY LIPOPROTEINS
  • LIPID PROFILE
  • TUMOR NECROSIS FACTOR INHIBITORS
  • CARDIOVASCULAR RISK

There are abundant data that rheumatoid arthritis (RA) is associated with an increased cardiovascular (CV) risk1. Multiple studies have shown that tumor necrosis factor (TNF) inhibitors reduce the CV risk in patients with established RA2. Suppression of inflammation, e.g., as a result of antiinflammatory treatment with TNF inhibitors, leads to increased high-density lipoprotein (HDL) levels, but also to increased total cholesterol (TC) levels with virtually no change in the TC/HDL ratio3, an important predictor of CV events4. Hence, the atheroprotective effect of TNF inhibitors appears not to be mediated by quantitative changes in the lipid profile.

Data indicate that TNF inhibitors induce structural changes in lipid but also protein composition, such as decreasing levels of the atherogenic serum amyloid A (SAA) within HDL particles5. These findings are important because they may explain the beneficial effect of anti-TNF treatment on CV risk.

We investigated the changes in HDL profiling in patients with RA who started treatment with TNF inhibitors. The patients were stratified for European League Against Rheumatism (EULAR) response.

MATERIALS AND METHODS

From 2 simultaneously running prospective cohorts at the Rheumatology Department of the Jan van Breemen Research Institute | Reade, Amsterdam, 100 patients with RA who were TNF-naive at baseline were randomly selected. Treatment allocation was at the discretion of the treating rheumatologist. The etanercept RA cohort comprised 203 patients and the adalimumab RA cohort comprised 204 patients. To distinguish between patients with low-grade and high-grade inflammation, only patients with sustained EULAR good or nonresponse at 1 and 4 months of TNF-blocking therapy were included, and moderate responders were excluded. Etanercept-treated patients were matched to adalimumab-treated patients for age, sex, disease duration, and baseline Disease Activity Score. In total, 50 EULAR good responders and 50 EULAR nonresponders were enrolled in our study. Clinical data and blood samples were collected at baseline and after 1 and 4 months of therapy.

The study was approved by the local Medical Ethics Committee and all patients gave written informed consent.

Assessment of lipids and HDL protein profiling

TC and triglycerides (TG) were measured by enzymatic methods using clinical chemistry analyzers. HDL was determined enzymatically with PEG-modified enzymes. Direct low-density lipoprotein (LDL) measurement was done with a kit from Wako Chemicals. Apolipoproteins (apo) were measured by an immunoturbidimetric method, using assays supplied by Randox Laboratories Limited. TC/HDL ratio and apoB/apoA-I ratios were calculated.

HDL profiling was assessed with surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF-MS)6,7.

HDL-associated proteins were measured directly from fresh frozen plasma and non-HDL components were eliminated using anti-apoA-I antibodies. SELDI-TOF-MS analysis was performed with a PBS IIc protein chip reader using an automated data collection protocol within protein-chip software. Data were collected up to 200 kDa. Laser intensity was set in a range from 190 to 220 relative units and the focus mass was set to 28 kDa for anti-apoA-I capture. Protein spectra were measured with about 100 shots at 13 positions per SELDI spot. The sensitivity of detection was set at signal/noise ratio > 5. Statistical analyses were performed using SPSS version 16.0. The differences between groups were tested using independent t test, chi-square test, or Mann-Whitney U test, as appropriate.

RESULTS

Clinical and demographic characteristics of all patients are shown in Table 1. There were no significant differences between etanercept- and adalimumab-treated patients (data not shown).

View this table:
  • View inline
  • View popup
Table 1.

Demographic and clinical characteristics at baseline. Mean values (SD), or mean ± SD, or count (percentage) are shown unless indicated.

Absolute changes in lipid levels were assessed using generalized estimating equation analysis. HDL and apoA did not change in EULAR nonresponders. In the EULAR good responders, however, HDL and apoA-II increased significantly after 1 and 4 months of therapy (Table 2).

View this table:
  • View inline
  • View popup
Table 2.

Changes in lipid levels according to EULAR response at 1 and 4 months of therapy.

At baseline there were no significant differences in HDL profiling between EULAR good responders and nonresponders. In total, 14 out of 133 mass charge markers changed during therapy, of which 4 were associated with SAA-1 and -2 (11092, 11540, 11696, 11750 m/z)7. After 1 month of therapy, marker 11750 was significantly higher in nonresponders compared to good responders (p = 0.036; Appendix 1 and Appendix 2). After 4 months of therapy, all markers representing SAA-1 and -2 were significantly higher in nonresponders than in good responders (all p < 0.05).

In addition, dynamics in markers associated with SAA-1 and -2 were assessed in EULAR good and nonresponders. SAA did not change in nonresponders at both 1 and 4 months of therapy. In contrast, in good responders after 1 month of therapy, marker 11750 decreased significantly compared to baseline (p < 0.05), whereas a clear decreasing trend in signal was observed in the other 3 markers. After 4 months of therapy, markers 11092, 11540, 11696 (p < 0.05), and 11750 (p < 0.001) decreased significantly compared to baseline (Figure 1).

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Dynamics of the serum amyloid A (SAA)-1 and -2 markers stratified for EULAR response. The mean values (± 1 SD) of the 4 markers correspond with the SAA isoforms as present in the nonresponders and responders. The corresponding timepoints are baseline (T0), 1 month (T1), and after 4 months after the start of therapy (T4). §p < 0.05, *p < 0.001 using 1-way ANOVA with Bonferroni multiple comparison. AU: arbitrary unit.

DISCUSSION

Our study reaffirms the beneficial effect of TNF inhibitors on structural changes in HDL protein composition5,8 and demonstrates, to our knowledge for the first time, that these findings apply only to RA patients with a good EULAR response, because HDL profiling did not change in EULAR nonresponders.

There is strong evidence that HDL is atheroprotective, although during inflammation the HDL protein composition changes, rendering HDL to a proinflammatory and atherogenic state9. For example, in response to inflammation, SAA replaces apoA-I from the HDL particle, resulting in a decreased ability of HDL to protect LDL from oxidation10.

The CV risk reduction by TNF inhibitors in patients with RA appears not to be mediated by quantitative changes of the lipids, because the effect on the atherogenic index is very modest3. Our data suggest that atheroprotective changes in HDL particle are the consequence of inflammation reduction by potent anti-TNF therapy. This was illustrated by the mass charge markers representing HDL-associated SAA-1 and -2, because these markers decreased significantly in good EULAR responders but did not change in EULAR nonresponders.

Inherent to the design of our study, selection bias should be taken into account. Moreover, the SELDI-TOF-MS approach was used to assess HDL profiling because of its strong applicability in high-throughput sample measurement. This method has limitations such as lack of direct protein identification6. However, protein profiling and not protein identification was the major objective in our study, justifying this approach.

Despite the limitations, our study clearly demonstrates that successful reduction of inflammation in RA patients with anti-TNF therapy restores the HDL protein composition to an atheroprotective profile, underscoring the need for tight inflammation control in patients with RA, to decrease the CV risk. However, it remains to be determined in longterm prospective studies whether these changes in the HDL protein composition translate into meaningful reduction of CV risk in patients with RA.

Acknowledgment

We are grateful to the Division of Research and Education of the Jan van Breemen Research Institute | Reade, which receives support from the Dutch Arthritis Foundation, for help in conducting the study. We thank the research nurses Marga Kammeijer-Rippen, Anne-Marie Abrahams, Martine Kos, and Astrid Twisk for performing clinical assessments. We also thank Margret de Koning for preparation of the assays.

Appendix 1

View this table:
  • View inline
  • View popup
  • Download powerpoint

Details of mass charge markers in nonresponders (signal in relative units).

Appendix 2

View this table:
  • View inline
  • View popup
  • Download powerpoint

Details of mass charge markers in responders (signal in relative units).

Footnotes

  • Supported by Pfizer (Wyeth) Pharmaceuticals and Abbott Laboratories; and facilitated by the Division of Research and Education of the Jan van Breemen Research Institute | Reade. Dr. Nurmohamed has received consultancy fees from Abbott, Roche, Pfizer, MSD, UCB, BMS, and Wyeth, and payment for lectures from Abbott, Roche, and Pfizer.

  • Accepted for publication February 22, 2013.

REFERENCES

  1. 1.↵
    1. Avina-Zubieta JA,
    2. Choi HK,
    3. Sadatsafavi M,
    4. Etminan M,
    5. Esdaile JM,
    6. Lacaille D
    . Risk of cardiovascular mortality in patients with rheumatoid arthritis: A meta-analysis of observational studies. Arthritis Rheum 2008;59:1690–7.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Westlake SL,
    2. Colebatch AN,
    3. Baird J,
    4. Curzen N,
    5. Kiely P,
    6. Quinn M,
    7. et al.
    Tumour necrosis factor antagonists and the risk of cardiovascular disease in patients with rheumatoid arthritis: A systematic literature review. Rheumatology 2011;50:518–31.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    1. Van Sijl AM,
    2. Peters MJ,
    3. Knol DL,
    4. de Vet RH,
    5. Sattar N,
    6. Dijkmans BA,
    7. et al.
    The effect of TNF-alpha blocking therapy on lipid levels in rheumatoid arthritis: A meta-analysis. Semin Arthritis Rheum 2011;41:393–400.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Di Angelantonio E,
    2. Sarwar N,
    3. Perry P,
    4. Kaptoge S,
    5. Ray KK,
    6. Thompson A,
    7. et al.
    Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009;302:1993–2000.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. van Eijk IC,
    2. de Vries MK,
    3. Levels JH,
    4. Peters MJ,
    5. Huizer EE,
    6. Dijkmans BA,
    7. et al.
    Improvement of lipid profile is accompanied by atheroprotective alterations in high-density lipoprotein composition upon tumor necrosis factor blockade: A prospective cohort study in ankylosing spondylitis. Arthritis Rheum 2009;60:1324–30.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Levels JH,
    2. Bleijlevens B,
    3. Rezaee F,
    4. Aerts JM,
    5. Meijers JC
    . SELDI-TOF mass spectrometry of high-density lipoprotein. Proteome Sci 2007;5:15.
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Levels JH,
    2. Geurts P,
    3. Karlsson H,
    4. Maree R,
    5. Ljunggren S,
    6. Fornander L,
    7. et al.
    High-density lipoprotein proteome dynamics in human endotoxemia. Proteome Sci 2011;9:34.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Watanabe J,
    2. Charles-Schoeman C,
    3. Milao Y,
    4. Elashoff D,
    5. Lee YY,
    6. Katselis G,
    7. et al.
    Proteomic profiling following immunoaffinity capture of HDL: Association of acute phase proteins and complement factors with pro-inflammatory HDL in rheumatoid arthritis. Arthritis Rheum 2012;64:1828–37.
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Heinecke JW
    . The HDL proteome: A marker — and perhaps mediator — of coronary artery disease. J Lipid Res 2009;50 Suppl:S167–71.
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    1. Rohrer L,
    2. Hersberger M,
    3. von Eckardstein A
    . High density lipoproteins in the intersection of diabetes mellitus, inflammation and cardiovascular disease. Curr Opin Lipidol 2004;15:269–78.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 40, Issue 6
1 Jun 2013
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
High-density Lipoprotein Profiling Changes in Patients with Rheumatoid Arthritis Treated with Tumor Necrosis Factor Inhibitors: A Cohort Study
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
High-density Lipoprotein Profiling Changes in Patients with Rheumatoid Arthritis Treated with Tumor Necrosis Factor Inhibitors: A Cohort Study
Anna Jamnitski, Johannes H. Levels, Inge A. van den Oever, Michael T. Nurmohamed
The Journal of Rheumatology Jun 2013, 40 (6) 825-830; DOI: 10.3899/jrheum.121358

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
High-density Lipoprotein Profiling Changes in Patients with Rheumatoid Arthritis Treated with Tumor Necrosis Factor Inhibitors: A Cohort Study
Anna Jamnitski, Johannes H. Levels, Inge A. van den Oever, Michael T. Nurmohamed
The Journal of Rheumatology Jun 2013, 40 (6) 825-830; DOI: 10.3899/jrheum.121358
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • Acknowledgment
    • Appendix 1
    • Appendix 2
    • Footnotes
    • REFERENCES
  • Figures & Data
  • References
  • Info & Metrics
  • PDF
  • eLetters

Keywords

RHEUMATOID ARTHRITIS
HIGH-DENSITY LIPOPROTEINS
LIPID PROFILE
TUMOR NECROSIS FACTOR INHIBITORS
CARDIOVASCULAR RISK

Related Articles

Cited By...

More in this TOC Section

  • Vasculitis: What Have We Learned in the Last 50 Years?
  • Demographic, Lifestyle, and Serologic Risk Factors for Rheumatoid Arthritis (RA)–associated Bronchiectasis: Role of RA-related Autoantibodies
  • Effectiveness of 6-month Use of Secukinumab in Patients With Psoriatic Arthritis in the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
Show more Articles

Similar Articles

Keywords

  • rheumatoid arthritis
  • HIGH-DENSITY LIPOPROTEINS
  • LIPID PROFILE
  • tumor necrosis factor inhibitors
  • cardiovascular risk

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • Privacy/GDPR Policy
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2022 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire